Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes

Figures & data

Table 1 Unique Risk Factors For Thrombotic Complications

Risk Factor	Comments
Gender Differences	Women: ↓ age at diagnosis ↑ rates of AVT
Driver Mutational Status	↑ JAK2 V617F allele burden
Inflammatory Markers	Role of Pentraxins: ↑ hs-CRP ↓ PTX3
Microparticles	MPs associated with: ↓ thrombin inhibition ↑ CD41 ↑ splenomegaly
Neutrophil Extracellular Trap Formations (NETs)	Result in NETosis and apoptosis

Abbreviation: AVT, abdominal vein thrombosis.

Table 2 Risk Factors For Post-PV MF And Leukemic Transformation

Risk Factor	Comments
Advanced Age	≥ 60 years old
Leukocytosis	WBC ≥15–30 × 10^9/L
JAK2 Allele Burden	Homozygous > Heterozygous
Non-Driver Mutations	Post PV MF: ASXL1, SRSF2, RUNX1, SF3B1, IDH1/2
	AML ASXL1,TP53, SRSF2, IDH1/2, RUNX1
Exposures to Therapies	Leukemogenic Risk Phosphorus-32(^32P), Chlorambucil, Pipobroman
	No Leukemogenic Risk Hydroxyurea (controversial), Busulfan, *Erythropoiesis stimulating agents (ESAs), *Splenectomy

Note: *Not reproducible and confounded by severe underlying disease.